Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06513949 · ClinicalTrials.gov registry record · Phase 2

Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients

A Phase 2 study of Acute Respiratory Distress Syndrome and Acute Lung Injury, sponsored by Implicit Bioscience.

Recruiting
Registry status
Phase 2
Development phase
56
Enrollment target
2
Study locations

NCT06513949 is a Phase 2 study of Acute Respiratory Distress Syndrome and Acute Lung Injury that is actively recruiting participants, run by Implicit Bioscience. The registered enrollment target is 56 participants, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (85% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06513949, a Phase 2 study of Acute Respiratory Distress Syndrome and Acute Lung Injury, is actively recruiting participants, sponsored by Implicit Bioscience.

RECRUITING
Registry status
Phase 2
Development phase
56 participants
Enrollment target
2
Study locations

Study Summary

Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.

Conditions Studied

Acute Respiratory Distress Syndrome Acute Lung Injury Adult Respiratory Distress Syndrome Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Interventions

  • OTHER Placebo
  • BIOLOGICAL Atibuclimab

Study Locations (2)

Washington

  • Harborview Medical Center - Seattle
  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2025-08-15
Est. Completion 2027-12
Phase Phase 2

Sponsor

Implicit Bioscience

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06513949

The ClinicalTrials.gov registry entry for NCT06513949 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (85% lower). The listed sponsor is Implicit Bioscience, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06513949 reports 2 study locations spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06513949 about?

NCT06513949 is a clinical study titled "Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients". Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.

What is the current status of trial NCT06513949?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-08-15. Estimated completion is 2027-12.

What conditions does trial NCT06513949 study?

This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome, Acute Lung Injury, Adult Respiratory Distress Syndrome, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS).

What interventions are being tested in trial NCT06513949?

The interventions under investigation include: Placebo (OTHER), Atibuclimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06513949?

This trial is sponsored by Implicit Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06513949 being conducted?

This trial has 2 study locations across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Respiratory Distress Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Respiratory Distress Syndrome

All registered trials for this condition

Acute Lung Injury

All registered trials for this condition

Washington

All trials with a study site in Washington

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.